Suzhou Chengyao's small molecule bioanalysis business has rich experience in areas with high technical difficulties, such as inhalants, liposomes, high sensitivity, instability, endogenous drugs, peptide drugs, etc., and has completed more than 100 innovations so far Drug clinical and preclinical pharmacokinetic studies and more than 200 generic drug consistency evaluation bioanalysis work. The team completed the complete preclinical and clinical pharmacokinetic evaluation and bioanalysis of innovative drugs approved by Hengrui Medicine, Qilu Pharmaceutical, Yangzijiang and other companies. Among the service items, flumatinib mesylate, famitinib malate, donafenib mesylate, vometinib, icotinib minophosphate, and S-1 capsules were approved for marketing, and another More than 50 new drugs have obtained clinical approval.

Suzhou Chengyao Macromolecular Bioanalysis Group is mainly engaged in the bioanalysis of clinical samples of monoclonal antibodies, polyclonal antibodies, ADCs, fusion proteins, peptides, gene therapy, vaccines, CAR-T, heparin, coagulation factors, etc. Detection of PK, ADA, Nab (binding experiment and cell experiment), biomarker, drug efficacy in vivo, flow cytometry, ELISPOT, etc.


In addition, Suzhou Chengyao is also equipped with exclusive QC, QA, sample management personnel and equipment management personnel according to a certain proportion to support the efficient operation of biological analysis.

equipment

XEVO-TQ-XS	QTRAT5500 Tandem Mass Spectrometer	Sciex 6500	XEVO G2-XSQTOF High Resolution Mass Spectrometry
PE VICTOR Nivo microplate reader	Flow BD Aria lll flow cytometer	Agilent7800ICP-MS	Agilent 6890N Gas Chromatograph







quality system